XML 77 R66.htm IDEA: XBRL DOCUMENT v3.25.3
Identifiable Intangible Assets, Net and Goodwill - Footnotes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 28, 2025
Sep. 28, 2025
Sep. 29, 2024
Indefinite-lived Intangible Assets [Line Items]      
Intangible asset impairment charge   $ 577  
Amortization expense for finite-lived intangible assets   3,600  
Developed technology rights [Member]      
Indefinite-lived Intangible Assets [Line Items]      
Intangible asset impairment charge [1]   14  
talazoparib (Talzenna) [Member] | Developed technology rights [Member]      
Indefinite-lived Intangible Assets [Line Items]      
Finite-lived intangible assets, period increase $ 600 590  
IPR&D [Member]      
Indefinite-lived Intangible Assets [Line Items]      
Intangible asset impairment charge [1],[2]   353  
IPR&D [Member] | Biopharma [Member]      
Indefinite-lived Intangible Assets [Line Items]      
Intangible asset impairment charge 260 260 $ 240
IPR&D [Member] | talazoparib (Talzenna) [Member]      
Indefinite-lived Intangible Assets [Line Items]      
Indefinite-lived intangible assets, period increase (decrease) $ (600) (590)  
License [Member] | Biopharma [Member]      
Indefinite-lived Intangible Assets [Line Items]      
Intangible asset impairment charge   $ 210  
[1] Reflects intangible assets written down to fair value in 2025. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
[2] See Note 9.